The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma

	patients (n = 237)	Controls (n = 193)	Test	OR (95% CI)	p
Gender
Male n (%)	175 (73.8%)	128 (66.3%)	χ² = 2.889	0.70	0.089
Female n (%)	62 (26.2%)	65 (33.7%)		(0.46–1.06)
Age
Years; median (25–75%)	66 (58–72)	56.2 (49.3–65.0)	U = 32583	1.08 (0.46–1.06)	< 0.001
Cumulative asbestos exposure¹
Low	36 (44.4%)	149 (77.2%)	χ² = 31.933		< 0.001
Medium	24 (29.6%)	15 (7.8%)
High	21 (25.9%)	29 (15.0%)
Low	36 (44.4%)	149 (77.2%)	χ² = 27.916	4.23³	< 0.001
Medium and high	45 (55.6)	44 (22.8%)		(2.44–7.36)
Smoking²
No	122 (53.0%)	106 (54.9%)	χ² = 0.149	1.08	0.699
Yes	108 (47.0%)	87 (45.1%)		(0.74–1.58)

[i] ¹ data available for 81 MM patients, ² data missing for 7 MM patients, ³ medium and high exposure in comparison to low exposure

Table 2

The influence of polymorphisms on MM risk

Polymorphism	Genotype	MM patients	Controls	Unadjusted risk		Adjusted risk by gender and age
		N (%)	N (%)	OR (95% CI)	p	OR (95% CI)	p
ERCC1 rs11615	TT	97 (41.8)¹	64 (35.8)²
	TC	94 (40.5)	87 (48.6)	0.78		0.69
	CC	41 (17.7)	28 (15.6)	(0.52–1.16)	0.213	(0.45–1.06)	0.091
ERCC1 rs3212986	GG	142 (59.9)	84 (47.7)³
	GT	77 (32.5)	75 (42.6)	0.61		0.52
	TT	18 (7.6)	17 (9.7)	(0.41–0.91)	0.014	(0.34–0.80)	0.003
XRCC1 rs1799782	CC	196 (86.0)⁴	171 (90.0)⁵	1.47		1.12
	CT	32 (14.0)	19 (10.0)	(0.80–2.69)	0.211	(0.58–2.16)	0.728
XRCC1 rs25487	CC	90 (38.0)	74 (42.8)⁶
	CT	125 (52.7)	79 (45.7)	1.22		1.03
	TT	22 (9.3)	20 (11.6)	(0.82–1.82)	0.327	(0.67–1.59)	0.890

[i] For determining MM risk, carriers of at least one polymorphic allele were compared to non-carriers

[ii] ¹missing data for 5 patients; ²missing data for 14 patients; ³missing data for 17 patients, ⁴missing data for 9 patients, ⁵missing data for 3 patients, ⁶missing data for 20 patients

Table 3

The influence of interactions between investigated genetic polymorphisms on MM risk

Gene 1			Gene 2			Interaction
Genotypes	OR (95% CI)	p	Genotypes	OR (95% CI)	p	OR (95% CI)	p
ERCC1 rs 11615	0.78		ERCC1 rs3212986	0.61		1.97¹
TC + CC vs. TT	(0.52–1.16)	0.213	GT + TT vs. GG	(0.41–0.91)	0.014	(0.42–9.17)	0.75
ERCC1 rs 11615	0.78		XRCC1 rs1799782	1.47		1.30²
TC + CC vs. TT	(0.52–1.16)	0.213	CT vs. CC	(0.80–2.69)	0.211	(0.37–4.52)	0.680
ERCC1 rs 11615	0.78		XRCC1 rs25487	1.22		0.79³
TC + CC vs. TT	(0.52–1.16)	0.213	CT + TT vs. CC	(0.82–1.82)	0.327	(0.34–1.86)	0.592
ERCC1 rs3212986	0.61		XRCC1 rs1799782	1.47		1.49⁴
GT + TT vs. GG	(0.41–0.91)	0.014	CT vs. CC	(0.80–2.69)	0.211	(0.42–5.21)	0.537
ERCC1 rs3212986	0.61		XRCC1 rs25487	1.22		0.65⁵
GT + TT vs. GG	(0.41–0.91)	0.014	CT + TT vs. CC	(0.82–1.82)	0.327	(0.29–1.47)	0.302
XRCC1 rs1799782	1.47		XRCC1 rs25487	1.22		2.41⁶
CT vs. CC	(0.80–2.69)	0.211	CT + TT vs. CC	(0.82–1.82)	0.327	(0.66–8.80)	0.182

[i] ¹ rs 11615 ERCC1 TC + CC vs. TT ^* rs3212986 ERCC1 GT + TT vs. GG; ² rs 11615 ERCC1 TC + CC vs. TT * rs1799782 XRCC1 CT vs. CC; ³ rs 11615 ERCC1 TC + CC vs. TT * rs25487 XRCC1 CT + TT vs. CC; ⁴ rs3212986 ERCC1 GT + TT vs. GG * rs1799782 XRCC1 CT vs. CC; ⁵ rs3212986 ERCC1 GT + TT vs. GG * rs25487 XRCC1 CT + TT vs. CC; ⁶ rs1799782 XRCC1 CT vs. CC * rs25487 XRCC1 CT + TT vs. CC

Table 4

The influence of interactions between the investigated polymorphisms and asbestos exposure on MM risk

Polymorphism	OR	95% CI	p
ERCC1 rs11615	3.61	1.12–11.66	0.032
ERCC1 rs3212986	1.93	0.61–6.10	0.262
XRCC1 rs1799782	1.85	0.33–10.48	0.489
XRCC1 rs25487	2.80	0.89–8.79	0.078

Table 5

The influence of interaction between ERCC1 rs11615 polymorphism and asbestos exposure on MM risk

	Asbestos exposure								OR for asbestos exposure inside category ERCC1
	Low				Medium and high				OR for asbestos exposure inside category ERCC1
ERCC1 rs11615	MM (N)	Controls (N)	OR (95% CI)	p	MM (N)	Controls (N)	OR (95% CI)	p	OR (95% CI)	p
TT	20	48	1	Ref.	14	16	2.10 (0.872.10 –5.10)	0.101	2.10 (0.872.10 –5.10)	0.101
TC+CC	15	91	0.40 (0.190.40 –0.84)	0.016	30	24	3.00 (1.423.00 –6.34)	0.004	7.58 (3.537.58 –16.31)	< 0.001
*OR for ERCC1* inside category asbestos exposure**			0.40 (0.19–0.84)	0.016			1.43 (0.58–4.50)	0.435

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/raon-2019-0016 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 206 - 212

Submitted on: Feb 6, 2019

Accepted on: Feb 25, 2019

Published on: Mar 14, 2019

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

malignant mesothelioma,

DNA repair mechanisms,

ERCC1,

XRCC1,

Related subjects:

© 2019 Kristina Levpuscek, Katja Goricar, Viljem Kovac, Vita Dolzan, Alenka Franko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 53 (2019): Issue 2 (June 2019)